AOD were defined as bisphosphonates, teriparatide, denosumab, and raloxifene. Prevalence and incidence were calculated, and prevalent use among women with forearm fracture was compared with the population in Nord-Trøndelag and Norway. Age-adjusted Poisson regression analyses for time trends and odds ratio for treatment with AOD was estimated. Adherence was defined as medication possession ratio ≥ 80 %. Results The first year after the fracture, 11.2 % of the women and 2.7 % of the men were prevalent users, while 5.1 % and 1.2 %, respectively, were incident users of AOD. Bisphosphonates comprised 98.8 %. AOD use among women with fractures was significantly higher compared to the gen- In women, 54.8 % were adherent during 3 years after fracture. Conclusions The use of AOD after a forearm fracture was low. An increased focus on osteoporosis in fracture patients is needed for secondary fracture prevention.
Background
Osteoporosis is a major health problem among the elderly, and Norway has the highest incidence of osteoporotic fractures reported [1, 2] . Osteoporosis is characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture [3] , and is defined by the World Health Organization (WHO) as a bone mineral density (BMD) of 2.5 standard deviations (SD) or more below the mean peak bone mass (average of young, healthy adults, T-score) [4] . In the USA, the hospitalization burden of osteoporotic fractures among women 55 years and older is found to be greater than that of myocardial infarction, stroke, or breast cancer [1] .
Forearm fractures are often a precursor of the more serious hip fractures, and several studies have shown that forearm fractures are associated with low BMD and subsequent fractures [5] [6] [7] [8] [9] . After a forearm fracture, the risk of a hip fracture or a vertebral fracture is increased approximately twice, while the risk for a new forearm fracture is raised more than threefold [5, 9] . A forearm fracture should thus be a reminder of the presence of osteoporosis and promote initiation of antiosteoporotic drugs (AOD).
However, despite effective drugs, treatment after fractures is rarely commenced [7, [10] [11] [12] [13] [14] . In Norway, only 16.9 % of women and 4.6 % of men were treated with AOD within 2 years after a hip fracture [10] . In the Netherlands, 15 % of patients were dispensed AOD within 1 year after discharge from hospital after a fall-related fracture, mostly hip fractures [11] . There exist few data regarding forearm fractures and treatment. In a US study from 1993-1997, 18 % of women with a low-energy forearm fracture received pharmacological intervention for osteoporosis within 12 months, and then mainly hormone replacement therapy (HRT) [7] . A recent study form France showed that only 10 % of women > 50 years underwent BMD assessment after a forearm fracture [12] . In Denmark, a study of 147 women with a forearm fracture reported that only 12 were referred to densitometry or spine X-ray [13] . A national analysis from Denmark also found a low use of AOD following forearm fracture. Hence, in 1997, only 2.1 % of women over 50 years with forearm fractures began treatment in the first year after fracture, and in 2004 this remained as low as 5.2 % [14] . AOD use was even lower in men. No data are published on treatment with AOD after a forearm fracture in Norway.
The primary aim of this study was to examine time trends in the prevalence and incidence of AOD use the first year after a forearm fracture in the period 2005-2012. Secondary aims were to investigate if gender, the number of drugs used before fracture, or use of glucocorticoids influenced the prescription of AOD, and to examine treatment adherence.
Material and methods

Study design
The present study is a cohort study based on linkage of data from the fracture registry covering the Norwegian county of Nord-Trøndelag (population size 133,390 in 2012) and the Norwegian Prescription database (NorPD, established in 2004).
Data sources
The fracture registry of Nord-Trøndelag
The fracture registry covers all forearm and hip fractures in persons older than 16 years treated or followed up in the only two hospitals in Nord-Trøndelag from August 15, 1995 to December 31, 2012 . The data were collected from the medical records through the electronic discharge registers, the Patient Administrative System (PAS) for the whole period, as well as the X-ray registry in the period August 15, 1995 to December 31, 2007 [15] .
Individuals with potential fractures were identified in PAS based on diagnoses according to the International Classification of Diseases (ICD), as well as surgical procedures according to the third version of the National Classification of Operations (SIFF-95) until December 31, 1998, and thereafter according to NOMESKO Classification of Surgical Procedures (NCSP). The ICD 10 codes included were S52.X and the NCSP codes: NCJ00-99; NCU39+49; TNC31-33 and 39. The fracture diagnoses were retrospectively validated by specially trained medical doctors, nurses, and health secretaries.
A fracture was defined when: 1) The ICD code was accompanied by a NCSP procedure code of reduction, surgical intervention, or intervention with a rigid device or 2) A fracture was diagnosed by X-ray. Fractures due to metastatic disease were excluded. When in doubt if there was a new fracture or a control of an earlier fracture, or if the procedure code was missing, the medical record was reviewed by a medical doctor.
The Norwegian Prescription Database
Data on use of AOD were drawn from the Norwegian Prescription Database (NorPD) [16] . Since January 1, 2004, all pharmacies in Norway have been obliged to submit data on all dispensed prescriptions electronically to the Norwegian Institute of Public Health on a monthly basis. NorPD contains information on all prescribed drugs, reimbursed or not, that are dispensed at all pharmacies in Norway to individual patients in ambulatory care. Drugs prescribed to hospitalized or other institutionalized patients are not registered in NorPD [17] . Each person is assigned a unique identifier, which makes it possible to follow chronologically all dispensed prescriptions to each individual.
Anti-osteoporotic drugs and drugs that influence bone
All drugs in Norway are classified according to the Anatomical Therapeutic Chemical (ATC) classification system [18] . For each prescription, the amount dispensed measured in defined daily doses (DDD) is registered in NorPD. In this study, the following drugs were defined as AOD: bisphosphonates (ATC code M05BA), teriparatide (H05AA02), denosumab (M05BX04), and raloxifene (G03XC01).
HRT, tibolone (G03CX01) as well as calcium supplement with or without vitamin D were not defined as AOD for the purpose of this analysis, although the use of these medications was included in the tabulations due to their positive effect on bone. HRT was defined as estrogens given as oral medication or patch (G03C), except estriol (G03CA04) which has not proven to prevent osteoporosis, as well as progestogens and estrogens in combination given as oral medication or patch (G03F).
Calcium supplements up to 1500 mg and vitamin D3 up to 20 μg are available without prescription in Norway [19] . The prescribed use of calcium and vitamin D (A12AX) will therefore underestimate the real consumption.
Use of glucocorticoids (H02AB) was registered as they are the only drug implemented in the WHO fracture risk assessment tool (FRAX) as a risk factor for osteoporosis [20] .
The total number of drugs, excluding AOD, the last year before suffering a fracture, was applied as a surrogate measure of comorbidity [10] . Analyses on the number of drugs of ATC groups were based on third-level pharmacological subgroups, which are broad groups of drugs. Examples are insulin (A10A) and antithrombotic agents (B01A).
Study population
The study population consisted of all women and men in Nord-Trøndelag 40-84 years who experienced their first forearm fracture between January 1, 2005 and December 31, 2012. Subjects with a previous fracture in the forearm or hip recorded in the Nord-Trøndelag fracture register (started in 1995) were excluded to avoid previous fractures as the indication for AOD treatment. Data from NorPD were collected from January 1, 2004 to December 31, 2013 , that is to include data minimum 365 days before and 365 days after the current forearm fracture.
Definitions
AOD
Anti-osteoporotic drugs were defined as bisphosphonates, teriparatide, denosumab, and raloxifene. The number of DDDs filled divided by number of days from first filled prescription after the forearm fracture to 3 years follow-up or death. Adherence MPR≥80 % from first filled prescription after the forearm fracture to 3 years follow-up or death.
Number of drugs
The total number of dispensed drugs with ACT codes on the third level 365 days before the fracture, excluding AOD. These were categorized according to quartiles: first quartile=0-1 drug, second quartile=2-3 drugs, third quartile=4-6 drugs, and fourth quartile ≥ 7 drugs. Age groups 40-59 years, 60-69 years, and ≥ 70 years.
Analysis strategy and statistics
Prevalence and incidence for different AOD, HRT, and supplements with calcium plus vitamin D the first year after the forearm fracture are presented and stratified for fracture year and gender. The incidence rates of fractures by age stratified for gender are presented per 1000.
In women, we calculated prevalent use of AOD the first year after a forearm fracture for each year in the period 2005-2012 and compared it with the prevalent use of AOD in NordTrøndelag, based on all individuals at the same age in the county, as well as the corresponding figures from the whole of Norway. Age standardization was done by the direct method using the mean age distribution 2005-2012 in women in Norway in 5-year age groups as standard population. Information about the population in Nord-Trøndelag and Norway was derived from the Statistics Norway [21] . Age-adjusted Poisson regression analyses were used for time trends in use of AOD among women with forearm fractures 2005-2012. Group analysis with skewed data was performed with Mann-Whitney U test.
To further study factors that influenced use of AOD, logistic regression models were applied in women. Separate analysis for men was not performed due to few cases. The following independent variables were included: age at fracture, number of drugs the last year before fracture, and use of glucocorticoids the last year before fracture. Medication possession rate and adherence were calculated according to the definitions for AOD among women; 95 % confidence intervals (CIs) for counts were calculated by the continuity-corrected score interval method [22] .
Statistical analyses were performed using IBM SPSS, V.20 (SPSS, USA), STATAV.13.0 (StataCorp, College Station, TX, USA) and Microsoft Excel 2010.
Ethics
The study was approved by the Regional Committee for Medical and Health Research Ethics in Central Norway. Linkage of databases was approved by the Norwegian Data Protection Authority and the Norwegian Institute of Public Health as the administrator of NorPD.
Results
Study population
The study population consisted of 1947 subjects, 1434 women and 513 men, diagnosed with a forearm fracture in the period 2005-2012. The mean age at fracture was 63.7 (SD 11.0) years for women and 57.4 (11.8)years for men. The incidence rates of fractures by age among men and women are presented in Fig. 1 .
Treatment with anti-osteoporotic drug and time trends
Altogether, 160 women (11.2 %) and 14 (2.7 %) men used AOD within the first year after a forearm fracture, of which 68 women (5.1 %) and 6 men (1.2 %) were incident users. Bisphosphonates comprised 98.8 % of the AOD use, and among the bisphosphonate users, 96.6 % used alendronate. None of the men used other AOD than bisphosphonates. The use of AOD, HRT, tibolone, and supplements of calcium with vitamin D among women is shown in Table 1 .
In Fig. 2 
Factors associated with AOD
The age-adjusted odds ratio for receiving AOD after a forearm fracture was 3.5 times higher in women than in men.
Factors influencing use of AOD in women are shown in Table 2 .
In the multivariate logistic regression model, the OR for being treated with AOD for the age group 60-69 years was more than four times higher compared to the youngest age group. For the oldest group, the OR was 3.3. Using more than four different drugs the last year before fracture was also associated with use of AOD with an OR of 2.4 (95 % CI 1.4-4.0). Among those using glucocorticoids the last year before fracture, the OR of receiving AOD was almost two. Of the 120 women using glucocorticoid (GC) the last year before fracture, those receiving AOD had used significantly more GC than the women not receiving AOD (median 600 DDD versus 175 DDD, p<0.001). In our material, 19 of the 20 women receiving AOD had used GC more than 3 months compared to 83 of the 93 not receiving AOD.
Adherence to treatment after fracture
Among prevalent female AOD users, 115 were followed for 3 years from the first prescription after the forearm fracture. Of these, 54.8 (95 % CI 48.7-67.3) were adherent. Five women of 115 filled only one prescription. For incident users (N=50), the adherence was 56.0 % (95 % CI 45.2-73.3), and three women filled only one prescription. The mean medication possession rate was 77.4 % (SD 33.0 %) and 76.3 % (SD 34.5 %) for prevalent and incident users, respectively.
Discussion
In the present study, we show that the use of AOD after a forearm fracture was low and did not increase Fig. 1 The incidence rate of fractures by age (per 1000) stratified for gender 
AOD Norway
Use of anti-osteoporotic drugs per 100 Fig. 2 Age-adjusted time trends in prevalence (%) of antiosteoporotic drug use among women in Nord-Trøndelag with a forearm fracture, compared to the anti-osteoporotic drug use among all women in Nord-Trøndelag and Norway which is higher than the AOD use in Norway [24, 25] . As indicated in our study, a declining use of bisphosphonates in secondary prevention of osteoporosis has also been reported from the USA [26] . In our study, almost no men were treated with AOD. One reason for this can be the fact that forearm fractures among men are more often high-energy fractures [27] , which is supported by the lower age in men compared to women. However, osteoporosis among men is probably underdiagnosed. In Norway, only 4.6 % of men 50 years or older were treated with AOD during 2 years after a hip fracture [10] and only 0.5 % of men over 40 years received AOD [24] .
There are several studies showing an increased risk of forearm fractures in individuals with osteoporosis as defined by WHO (T-score <−2.5 SD), and that those suffering a forearm fracture have an increased risk for subsequent fractures [5, 9, 28, 29] . The rapid increase in the incidence of forearm fractures among women after 50 years also supports that bone loss after menopause is a major risk factor for fractures [27, 30] . In women > 70 years, an increased mortality has been reported after a forearm fracture, suggesting that this fracture is more serious than previously assumed [31, 32] . Based on these facts, the use of AOD in Nord-Trøndelag after a forearm fracture is clearly too low.
Bisphosphonates and especially alendronate were the drugs of choice among AOD. The reimbursement rules in Norway for AOD did change during the period. Up to 2012, AOD was only fully reimbursed after a fracture had occurred and from 2006-2011 a BMD measurement was required. Alendronate was the drug of choice due to cost, and other drugs were only indicated if alendronate could not be used due to side effects or comorbidity [24] . Zolendronic acid can be dispensed both in ambulatory care as well as in hospitals in Norway. As drugs given in hospital are not included in the NorPD, the use of zolendronic acid may be underestimated.
The adherence of 54.8 % after 3-year follow-up is comparable to other observational studies both in Norway and other countries [33, 34] . In a review of large observational studies, the adherence (defined as MPO ≥80 %) was reported to range from 33 to 50 % [34] . There are different methods for calculating MPR, and we have chosen the same definition as Devold in a previous study from Norway [33] . The low adherence is a major challenge for bisphosphonates given orally. Side effects from the gastrointestinal tract are probably the most common reason to stop the treatment, as well as the complex regimen regarding oral administration [35] . In addition, concerns about safety aspects such as osteonecrosis of the jaw and atypical femur fractures contribute to the low adherence, although these are concerns that apply mainly to long-term treatment, generally in excess of 5 years [36, 37] .
The use of HRT among women with forearm fracture in Nord-Trøndelag was low, and HRT seemed to be used for other purposes than osteoporosis, which is in accordance with current national and international guidelines [38] [39] [40] . HRT was the treatment of choice for osteoporosis until 2002, when it was described to have adverse effects when assessing health benefits and risks in the Women's Health Initiative Study [41] . In the Norwegian guidelines from 2005 [38] , HRT is only recommended for osteoporosis in women with postmenopausal complaints and then only for short duration. Even if later studies have questioned these findings [42, 43] , there was no increase in the use of HRT during our study.
We found that treatment with glucocorticoids the last year before fracture was associated with AOD use, but only 22.5 % of those who were using glucocorticoids were treated with AOD. Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis, and it is estimated that 30 % of all patients treated with glucocorticoids for 6 months or more will develop osteoporosis [35] . The latest recommendations from the International Osteoporosis Foundation and the European Calcified Tissue Society advise to consider AOD in all patients given orally glucocorticoids for 3 months or more [44] . In our material, women prescribed AOD had used significantly more glucocorticoids than women not using AOD. However, 83 of the 93 women not receiving AOD had used glucocorticoids more than 3 months. Based on these facts, the proportion of AOD users among glucocorticoids users is too low in our material.
Further, the number of drugs prescribed the last year before fracture predicted the use of AOD. The number of different drugs used can be interpreted as a crude measure of comorbidity. This may suggest that the awareness of osteoporosis is higher when the patients are frail and diseased. Another explanation can be that patients who use many drugs are more health-conscious and make more visits to their general practitioner [10] . We do not have information to explore this further.
The strength of this study is the use of large registers and the long follow-up time.
However, our study also has limitations. The most important is that we do not have any information about the fall mechanism or if it was a high-or low-energy fracture, and the study does not include data on BMD or other risk factors for osteoporosis. Further, we have registered dispensed medication, but we are not aware if the drug has actually been taken. Finally, the prescription register does not record medications given to patients in nursing homes or hospitals. This may lead to an underestimation of the AOD use in the oldest. However, we have excluded subjects above 85 years to reduce this bias.
Osteoporosis is still a major health problem and the burden of osteoporotic fractures is high both for the patient and the society [1] . Despite available and low-cost treatment, the use of AOD is low and there is a substantial treatment gap. The establishment of Fracture Liaison Services, where all patients with a fracture are evaluated for osteoporosis, has been shown to be an effective intervention to prevent secondary fractures [45] . Further, patient education about osteoporosis and fracture risk is found to increase the adherence to AOD [35, 45] .
In conclusion, the use of AOD in central Norway after a forearm fracture, as well as adherence, was low. There was a trend towards a decline in AOD use among women with fractures from 2005 to 2012. An increased focus of osteoporosis in both patients and doctors is needed to prevent a secondary fracture.
